How Long Does It Take for Tirzepatide to Leave Your System?

Tirzepatide has a half-life of approximately five days, giving a full clearance window of roughly four to five weeks after the last injection.
Side effects (particularly nausea and digestive changes) may persist for one to two weeks after stopping, even as blood levels fall.
Contraception containing oestrogen (oral pills) can be less reliably absorbed for four weeks after each dose increase; discuss contraceptive cover with your prescriber before stopping treatment.
There is no licensed reversal agent; clearance happens at the body's own pace, so planning around surgery or pregnancy requires advance discussion with a clinician.

Tirzepatide takes roughly five weeks to clear from your body after your last dose. Its half-life is approximately five days, meaning the medicine halves in concentration every five days — so after five half-lives (around 25 days), less than four percent remains. That said, the clinical effects on appetite and digestion can linger well into that window, which catches many people off guard. Tirzepatide is a prescription-only medicine; a qualified prescriber assesses suitability before it is dispensed, and decisions about stopping, pausing or switching should always involve that prescriber.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The timeline, the misconceptions, and what it means in practice

The biggest misconception: stopping your pen does not mean tirzepatide leaves overnight

Most people assume that once they skip an injection, tirzepatide is gone within a day or two — as if the body flushes it the moment supply stops. That is not how this medicine works. Tirzepatide is absorbed slowly from the subcutaneous tissue (the layer just beneath the skin where you inject), then broken down through normal protein metabolism. The published half-life sits at around five days. Run the arithmetic: after ten days, roughly a quarter of the last dose remains active; after 25 days you are below the four-percent threshold most pharmacologists use as a practical marker for clearance.

In real terms, expect tirzepatide to be substantially gone from your system within four weeks of your last injection, and fully cleared by around five weeks. The NHS tirzepatide medicines page confirms that the medicine is eliminated over time without any requirement for a reversal treatment. Practically, this means appetite suppression and the slowing of gastric emptying may still be noticeable one to two weeks after your final dose, some people find eating patterns shift back gradually, others feel the change more sharply. Neither experience is unusual.

If you want to understand how long tirzepatide actively works during a treatment week (a different question), this page covers how long tirzepatide remains active between doses.

Why the clearance timeline matters more than most people realise

Knowing when tirzepatide leaves your system is not just academic. Several practical situations depend on it. Surgery is the most urgent: anaesthetists need to know you are on a GLP-1 medicine because gastric emptying slows on treatment, raising aspiration risk under general anaesthetic. NHS England advises telling your surgical team and anaesthetist in advance, and if your procedure is elective, your prescriber may recommend pausing treatment ahead of it. The window varies by individual and procedure, so this conversation should happen well before any planned operation date.

Pregnancy planning is the other major consideration. These medicines are not recommended in pregnancy, while breastfeeding, or in the period when someone is actively trying to conceive. Because tirzepatide takes around five weeks to clear, planning needs to start earlier than people expect. Contraception is relevant here too: for women taking oral contraceptive pills, the MHRA and NHS England guidance notes that tirzepatide's effect on gastric emptying may reduce pill absorption, particularly for the first four weeks of treatment and for four weeks after any dose increase. A non-oral method (such as condoms) is advised during those windows. If you are stopping tirzepatide because you want to conceive, the right moment to stop, and how long to wait, is a conversation for your prescriber rather than a rule-of-thumb from a webpage.

The broader treatment picture (including how quickly tirzepatide begins working in the first place) is covered in our guide on how long tirzepatide takes to work.

What happens to weight and appetite after tirzepatide clears

Clinical trials show that much of the weight lost on tirzepatide is regained over time once treatment stops. This is not a failure of willpower; it reflects the biology of appetite regulation. The hormonal signals that tirzepatide mimics (GLP-1 and GIP receptor activity) return to their pre-treatment baseline as the medicine clears. For many people, hunger returns noticeably within two to three weeks of stopping.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, involved 2,539 adults and showed average weight reductions of around 20–21 percent at the 15 mg dose over 72 weeks. Extension and withdrawal data from tirzepatide studies consistently show that stopping treatment reverses a significant proportion of those losses over the following year. This does not mean treatment is pointless; it means treatment duration is a clinical decision, not something to cut short without a plan. Our Mounjaro overview covers the full picture of how tirzepatide works and what the trial evidence shows.

If you have been on a higher dose and are considering stopping or stepping down, the relationship between dose strength and how long tirzepatide stays detectable is worth reading before that conversation with your prescriber. And if you are weighing up Mounjaro against other treatments, the weight loss treatment overview sets out the licensed options in plain terms.

When clearance becomes an urgent clinical question

For most people stopping tirzepatide, the five-week clearance window is background information. For a smaller group, including those facing urgent surgery, those who develop a serious side effect and need the medicine out of their system as quickly as possible, or those who become pregnant unexpectedly, it becomes pressing, and our page on how long tirzepatide stays in your system explains the pharmacology behind that timeline in more detail. There is no antidote and no licensed way to accelerate clearance. Supportive care (fluids, rest, symptom management for any side effects) is what clinicians can offer in the interim.

Suspected side effects can and should be reported to the MHRA via the Yellow Card scheme, that data genuinely shapes future safety guidance. If you experience severe, persistent abdominal pain that spreads to the back, seek urgent medical attention rather than waiting for clearance; this is the warning sign for pancreatitis that the MHRA highlighted in its January 2026 Drug Safety Update on GLP-1 medicines.

Questions about your own treatment (whether to pause, stop, switch or continue) belong with a prescriber who knows your history. Our clinical team, led by our GPhC-registered Independent Prescribers, is available seven days a week for aftercare. If you are not yet a patient and want to explore whether Mounjaro is appropriate for you, you can check your eligibility with a free consultation. For answers to common questions not covered above, including how long Mounjaro takes to leave your system after your last dose, the FAQs page is a good starting point.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions